Compile Data Set for Download or QSAR
Report error Found 33 Enz. Inhib. hit(s) with all data for entry = 571
TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202585(US9238625, 8j | US10035761, Compound 8j)
Affinity DataKi:  0.800nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202585(US9238625, 8j | US10035761, Compound 8j)
Affinity DataKi:  1.16nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202584(US9238625, 8h | US10035761, Compound 8h)
Affinity DataKi:  1.19nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202582(US9238625, 8a | US10035761, Compound 8a)
Affinity DataKi:  1.40nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202582(US9238625, 8a | US10035761, Compound 8a)
Affinity DataKi:  2.38nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202584(US9238625, 8h | US10035761, Compound 8h)
Affinity DataKi:  2.39nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202581(US9238625, 7g | US10035761, Compound 7g)
Affinity DataKi:  2.99nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202587(US9238625, 12c | US10035761, Compound 12c)
Affinity DataKi:  3.31nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202583(US9238625, 8d | US10035761, Compound 8d)
Affinity DataKi:  3.80nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202583(US9238625, 8d | US10035761, Compound 8d)
Affinity DataKi:  5.45nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202585(US9238625, 8j | US10035761, Compound 8j)
Affinity DataKi:  11nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202584(US9238625, 8h | US10035761, Compound 8h)
Affinity DataKi:  12.7nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202588(US9238625, 13c | US10035761, Compound 13c)
Affinity DataKi:  14.8nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202588(US9238625, 13c | US10035761, Compound 13c)
Affinity DataKi:  17.1nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202586(US9238625, 12b | US10035761, Compound 12b)
Affinity DataKi:  18.8nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202588(US9238625, 13c | US10035761, Compound 13c)
Affinity DataKi:  23.9nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202591(US9238625, 17a | US10035761, Compound 17a)
Affinity DataKi:  29.4nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202581(US9238625, 7g | US10035761, Compound 7g)
Affinity DataKi:  37.2nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202591(US9238625, 17a | US10035761, Compound 17a)
Affinity DataKi:  38.4nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202591(US9238625, 17a | US10035761, Compound 17a)
Affinity DataKi:  44.7nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202582(US9238625, 8a | US10035761, Compound 8a)
Affinity DataKi:  46.7nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM279459(US10035761, Compound 13f | Example 57 1-(1-(3,4-di...)
Affinity DataKi:  49.2nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202589(US9238625, 13d | US10035761, Compound 13d)
Affinity DataKi:  51nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202586(US9238625, 12b | US10035761, Compound 12b)
Affinity DataKi:  51.9nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202589(US9238625, 13d | US10035761, Compound 13d)
Affinity DataKi:  65.3nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202586(US9238625, 12b | US10035761, Compound 12b)
Affinity DataKi:  67.6nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202583(US9238625, 8d | US10035761, Compound 8d)
Affinity DataKi:  72nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202581(US9238625, 7g | US10035761, Compound 7g)
Affinity DataKi:  92nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202589(US9238625, 13d | US10035761, Compound 13d)
Affinity DataKi:  104nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent dopamine transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202587(US9238625, 12c | US10035761, Compound 12c)
Affinity DataKi:  116nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM279459(US10035761, Compound 13f | Example 57 1-(1-(3,4-di...)
Affinity DataKi:  119nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent serotonin transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM279459(US10035761, Compound 13f | Example 57 1-(1-(3,4-di...)
Affinity DataKi:  224nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Revivia Pharmaceuticals

US Patent
LigandPNGBDBM202587(US9238625, 12c | US10035761, Compound 12c)
Affinity DataKi:  1.42E+3nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
In DepthDetails
US Patent